- Home
- BELFB vs COGT Comparison
BELFB vs COGT Comparison
Compare BELFB & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- COGT
- Stock Information
- Founded
- BELFB 1949
- COGT 2014
- Country
- BELFB United States
- COGT United States
- Employees
- BELFB N/A
- COGT N/A
- Industry
- BELFB
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- COGT Health Care
- Exchange
- BELFB Nasdaq
- COGT Nasdaq
- Market Cap
- BELFB 1.0B
- COGT 895.8M
- IPO Year
- BELFB N/A
- COGT 2018
- Fundamental
- Price
- BELFB $82.43
- COGT $8.20
- Analyst Decision
- BELFB Strong Buy
- COGT Buy
- Analyst Count
- BELFB 3
- COGT 6
- Target Price
- BELFB $98.33
- COGT $14.17
- AVG Volume (30 Days)
- BELFB 61.5K
- COGT 1.4M
- Earning Date
- BELFB 02-19-2025
- COGT 02-24-2025
- Dividend Yield
- BELFB 0.34%
- COGT N/A
- EPS Growth
- BELFB N/A
- COGT N/A
- EPS
- BELFB 4.32
- COGT N/A
- Revenue
- BELFB $524,943,000.00
- COGT N/A
- Revenue This Year
- BELFB N/A
- COGT N/A
- Revenue Next Year
- BELFB $0.77
- COGT N/A
- P/E Ratio
- BELFB $18.68
- COGT N/A
- Revenue Growth
- BELFB N/A
- COGT N/A
- 52 Week Low
- BELFB $45.75
- COGT $4.28
- 52 Week High
- BELFB $92.61
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- BELFB 54.33
- COGT 49.78
- Support Level
- BELFB $78.81
- COGT $6.60
- Resistance Level
- BELFB $80.80
- COGT $8.72
- Average True Range (ATR)
- BELFB 2.60
- COGT 0.52
- MACD
- BELFB 0.02
- COGT 0.11
- Stochastic Oscillator
- BELFB 81.93
- COGT 75.47
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.